Efficacy of S-1 in colorectal cancer

Positive reactions of hospital staff to feedback by specialists.

(2017) Nana Nakamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

(2014) Xunlei Zhang et al.   PLoS One

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

(2013) Yasuhide Yamada et al.   LANCET ONCOLOGY

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

(2013) Tsunekazu Mizushima et al.   ONCOLOGY

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer

(2012) Yoshito Komatsu et al.   ACTA ONCOLOGICA

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

(2012) I Mochizuki et al.   BRITISH JOURNAL OF CANCER

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer

(2012) H Baba et al.   BRITISH JOURNAL OF CANCER

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

(2012) Yong Sang Hong et al.   LANCET ONCOLOGY

Safety Verification Trials of mFOLFIRI and Sequential Irinotecan + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

(2012) Shunsuke Kato et al.   ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

(2011) Yasuhide Yamada et al.   INVESTIGATIONAL NEW DRUGS

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

(2011) Mitsuru Sasako et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

(2011) Yoshito Komatsu et al.   ONCOLOGY

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

(2010) Manabu Shiozawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer

(2010) Hirose   ONCOLOGY REPORTS

S-1: a promising new oral fluoropyrimidine derivative

(2009) Muhammad Wasif Saif et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

(2009) A. Tsunoda et al.   ONCOLOGY

Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004

(2008) H. J. Meulenbeld et al.   ANNALS OF ONCOLOGY

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

(2008) Y Yamada et al.   BRITISH JOURNAL OF CANCER

The Unanswered Question: What Is the Determinant of S-1 Pharmacokinetics?

(2008) W Ichikawa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas

(2008) T. Shirasaka   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY